Type-2 inflammation blockade in chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis with nasal polyps (CRSwNP) is, in most Western patients, a disease of dysregulated type-2 immunity. Epithelial damage triggers a cytokine cascade — IL-4, IL-13 and IL-5 — that recruits eosinophils and primes mast cells, producing the edematous, glistening polyps that obstruct the nasal airway and blunt the sense of smell.
CRSwNP is defined by ≥12 weeks of nasal obstruction, discharge, facial pressure and/or hyposmia, accompanied by bilateral polyps visible on endoscopy or CT. It sits on a spectrum with CRS without polyps (CRSsNP), but the two have distinct inflammatory signatures: CRSsNP is frequently neutrophilic/Th1-skewed, while CRSwNP in Western populations is overwhelmingly eosinophilic and type-2-skewed.
Polyps are outpouchings of edematous sinonasal mucosa — not neoplastic growths — that arise from chronic inflammation, epithelial barrier breakdown and impaired mucociliary clearance. Comorbid asthma is present in 30–70% of CRSwNP patients, and the subset with aspirin-exacerbated respiratory disease (AERD, Samter's triad: asthma + nasal polyps + aspirin/NSAID sensitivity) tends to have the most severe, treatment-refractory disease.
Mechanical or microbial injury to the sinonasal epithelium releases the "alarmin" cytokines TSLP, IL-25 and IL-33. These activate group 2 innate lymphoid cells (ILC2) and polarize naive CD4+ T cells toward the Th2 phenotype.
Activated ILC2 and Th2 cells secrete three signature cytokines:
• IL-4 — drives B-cell class switching to IgE and reinforces Th2 polarization • IL-13 — the dominant driver of goblet-cell metaplasia, mucus hypersecretion (MUC5AC) and epithelial barrier dysfunction; shares the IL-4Rα receptor subunit with IL-4 • IL-5 — the principal eosinophil growth, activation and survival factor, promoting eosinophilopoiesis in the bone marrow and prolonging eosinophil survival in tissue from days to weeks
IL-4 also licenses IgE production, which coats mast cells via the high-affinity FcεRI receptor, sensitizing them for degranulation on antigen re-exposure.
Up to 80–90% of nasal polyp tissue in Western patients shows dense eosinophilic infiltration (often >60 eosinophils per high-power field), a pattern distinct from the more neutrophilic endotype reported in many East Asian CRSwNP cohorts.
Polyps form through a self-amplifying loop of tissue edema, extracellular matrix remodeling and impaired epithelial repair. Vascular permeability increases, allowing plasma proteins (notably albumin and fibrin) to leak into the interstitium and form a pseudocyst-like stroma with markedly reduced fibroblast and gland density compared with normal mucosa.
Eosinophils release toxic granule proteins (major basic protein, eosinophil cationic protein) that further damage the epithelium, perpetuating the alarmin-driven cascade. Left unchecked, this drives progressive polyp growth, worsening obstruction and anosmia — and a strong tendency to recur after purely mechanical treatment such as endoscopic sinus surgery (FESS) unless the underlying inflammation is also addressed.
Not every CRSwNP patient benefits equally from every biologic. Endotyping — measuring blood and tissue eosinophils, total IgE, and comorbid asthma/AERD status alongside the endoscopic Nasal Polyp Score — identifies the dominant inflammatory driver and points to whichever of the three approved monoclonal antibodies is most likely to work.
Candidacy for biologic therapy is assessed after failure of standard-of-care: intranasal corticosteroids, saline irrigation, and often a prior endoscopic sinus surgery. Endotyping combines:
• Blood eosinophil count — a practical, widely available surrogate for type-2 activity; ≥150–300 cells/µL is generally considered type-2-high • Tissue eosinophil density — eosinophils per high-power field on polyp histology, a more direct but invasive measure • Total and specific serum IgE — supports an IgE/allergic component and omalizumab eligibility • Comorbid asthma/AERD — strongly predicts a type-2-high, biologic-responsive phenotype • Nasal Polyp Score and SNOT-22 quality-of-life questionnaire — quantify baseline severity and track response
All three approved agents converge on the same type-2 cascade but intercept it at different nodes:
• Dupilumab — blocks IL-4Rα, the shared receptor subunit for both IL-4 and IL-13, shutting down two cytokines with one antibody • Omalizumab — binds free circulating IgE, preventing it from occupying FcεRI on mast cells and basophils, so degranulation cannot be triggered • Mepolizumab — neutralizes IL-5 directly, starving eosinophils of their principal survival and maturation signal
Choice depends on the dominant driver: a patient with severe comorbid asthma and very high IgE may favor omalizumab; one with striking peripheral eosinophilia may favor mepolizumab; dupilumab's dual IL-4/IL-13 blockade gives it the broadest label and the largest CRSwNP evidence base.
Guidelines typically reserve biologics for patients with bilateral polyps, NPS ≥4, and persistent symptoms (obstruction, loss of smell) despite intranasal steroids and at least one prior sinus surgery — positioning biologics as an add-on or alternative to revision surgery, not a first-line therapy.
Real-world selection also weighs practical factors: dosing frequency and route (all three are subcutaneous injections, self-administered after training), comorbid indications already carried by the drug (dupilumab also treats atopic dermatitis and asthma; omalizumab also treats allergic asthma and chronic urticaria; mepolizumab also treats eosinophilic asthma and EGPA), payer/formulary coverage, and patient preference regarding injection interval (every 2 weeks for dupilumab; every 2–4 weeks weight/IgE-based for omalizumab; every 4 weeks for mepolizumab).
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Dupilumab | IL-4Rα (blocks IL-4 & IL-13) | Binds the shared IL-4Rα subunit, blocking type I and type II receptor signaling and downstream STAT6 activation | SINUS-24/52: NPS −2.06 pts vs placebo; UPSIT +10.9 pts |
| Omalizumab | Free serum IgE | Binds circulating IgE, preventing FcεRI engagement on mast cells/basophils and reducing IgE receptor density over time | POLYP 1/2: NPS −1.08 to −1.11 pts vs placebo |
| Mepolizumab | IL-5 | Neutralizes IL-5, reducing eosinophil maturation, activation and tissue/blood survival | SYNAPSE: NPS −1.68 pts vs placebo at week 52 |
Once injected subcutaneously and absorbed into the circulation, the monoclonal antibody reaches the sinonasal mucosa and binds its target with high affinity and specificity — a Y-shaped protein locking onto a single receptor or cytokine and physically preventing the type-2 cascade from continuing downstream.
Dupilumab is a fully human IgG4 monoclonal antibody that binds the extracellular domain of IL-4Rα with sub-nanomolar affinity. Because IL-4Rα is the shared subunit of both the type I receptor (IL-4Rα + γc, used by IL-4) and the type II receptor (IL-4Rα + IL-13Rα1, used by both IL-4 and IL-13), a single antibody simultaneously blocks two of the three core type-2 cytokines.
Once bound, dupilumab sterically prevents IL-4 or IL-13 from engaging their receptor complex, so the intracellular Janus kinase (JAK1/JAK2/TYK2) cannot be recruited and no downstream signal is transmitted — the cytokine may still be present in the tissue, but its message can no longer be delivered.
Because IL-4Rα sits at the convergence point of IL-4 and IL-13 signaling, one antibody achieves what would otherwise require blocking two separate cytokines and their receptors — a key reason dupilumab has the broadest efficacy data of the three approved agents.
Omalizumab binds the Cε3 domain of free IgE — the same region IgE uses to dock onto FcεRI — at a site that does not overlap with pre-bound IgE, so it cannot cross-link and trigger already-sensitized mast cells. Over weeks of therapy, free IgE levels fall and FcεRI receptor density on mast cells and basophils progressively downregulates, raising the threshold for degranulation.
This reduces mast-cell-driven histamine, leukotriene and cytokine release that both directly causes symptoms (itching, rhinorrhea) and indirectly amplifies the Th2/eosinophil cascade.
Mepolizumab is a humanized IgG1 antibody that binds IL-5 directly in the circulation and tissue, preventing it from engaging the IL-5 receptor alpha chain on eosinophils and their bone-marrow precursors. Without IL-5 signaling, eosinophil maturation in the marrow slows, and tissue eosinophils lose their principal anti-apoptotic survival signal, undergoing programmed cell death rather than persisting and degranulating in the polyp stroma.
Blood eosinophil counts typically fall by roughly 80–90% within weeks of starting anti-IL-5 therapy, though a small transient rise can occur very early as marrow-released cells briefly circulate before the drop.
Blocking the receptor is only the first step — the therapeutic payoff comes from what fails to happen next. With the JAK–STAT6 relay silenced and eosinophil survival signaling withdrawn, the transcriptional programs that build and maintain nasal polyps lose their fuel over the following weeks.
Under normal conditions, IL-4 or IL-13 binding to their receptor complex recruits and activates Janus kinases (JAK1, JAK2, TYK2), which phosphorylate STAT6. Phosphorylated STAT6 dimerizes, translocates to the nucleus, and switches on a broad transcriptional program: goblet-cell differentiation genes, the mucin gene MUC5AC, the eosinophil chemoattractant eotaxin-3 (CCL26), IgE class-switch machinery in B cells, and the extracellular matrix marker periostin.
With IL-4Rα occupied by dupilumab (or IL-13/IL-4 unable to signal), this entire cascade is interrupted at its origin — no receptor engagement means no JAK activation, no STAT6 phosphorylation, and no downstream transcription, regardless of how much cytokine is still circulating in the tissue.
Two independent mechanisms converge to deplete tissue eosinophils during this phase: reduced eotaxin-3 production (fewer chemotactic signals pulling new eosinophils into the mucosa) and, for anti-IL-5 therapy, withdrawal of the eosinophil survival signal itself. Circulating eosinophil counts typically fall by roughly half within the first 4–8 weeks and continue declining toward normal range by 16–24 weeks, tracking closely with reductions in tissue eosinophil density seen on repeat biopsy in clinical trials.
A transient early rise in blood eosinophils is sometimes seen in the first 1–4 weeks of anti-IL-5 or anti-IL-4Rα therapy as cells already committed to maturation are released from the marrow — this is expected and does not indicate treatment failure.
As mucin overproduction, vascular leak and eosinophil-driven tissue damage subside, the sinonasal epithelium begins to repair its barrier function. Fibrin and albumin deposition in the polyp stroma decreases, interstitial edema resolves, and the loose, pseudocyst-like polyp tissue gradually becomes denser and smaller — the structural basis for the clinical polyp shrinkage seen over the following months.
The cumulative effect of sustained type-2 blockade is measured in weeks to months, not days. Randomized trials of all three biologics show significant, durable reductions in polyp size, restoration of smell, and meaningful quality-of-life gains — frequently reducing or eliminating the need for revision sinus surgery or repeated courses of systemic corticosteroids.
Dupilumab (SINUS-24 and SINUS-52, Bachert et al., Lancet 2019) enrolled patients with severe CRSwNP despite prior surgery/steroids and showed a least-squares mean NPS reduction of −2.06 points versus −0.40 for placebo at week 24, alongside a −10.8 point improvement in Lund-Mackay CT opacification score and a +10.9 point gain in UPSIT smell testing. Benefits were sustained through 52 weeks.
Omalizumab (POLYP 1 and POLYP 2, Gevaert et al., JACI 2020) showed NPS reductions of roughly −1.08 to −1.11 points versus placebo at week 24, with parallel improvements in nasal congestion and SNOT-22.
Mepolizumab (SYNAPSE, Han et al., Lancet Respiratory Medicine 2021) demonstrated an NPS reduction of about −1.68 points versus placebo at week 52, with a significantly reduced need for surgery in the treatment arm.
Patients and clinicians typically observe a staged response:
• Weeks 1–4: eosinophil counts begin shifting; symptom diaries may show early, modest improvement in congestion • Weeks 4–8: smell scores (UPSIT) and nasal obstruction begin measurable improvement; some patients regain smell for the first time in years • Weeks 16–24: endoscopic Nasal Polyp Score shows its largest reduction; SNOT-22 quality-of-life scores cross the clinically important difference threshold • Weeks 24–52: benefits plateau at a durable, substantially improved baseline as long as therapy continues
Endoscopic sinus surgery (FESS) mechanically removes polyp tissue and opens sinus drainage pathways but does not address the underlying type-2 inflammation — recurrence rates after FESS in type-2-high patients approach 40% within 18 months. Biologics instead treat the inflammatory driver itself, and trial data show they can reduce the need for revision surgery and systemic corticosteroid courses by roughly 70% relative to placebo/standard care.
In practice the two approaches are often complementary rather than competing: surgery can restore anatomic access and drainage in severely obstructed sinuses, while a biologic controls the inflammation that would otherwise drive recurrence.
Discontinuing a biologic generally leads to gradual symptom and eosinophil relapse over subsequent months, since the underlying type-2 predisposition is suppressed, not cured — durable control currently requires continued dosing, an important discussion point in long-term treatment planning.